尼罗替尼在细胞系或原发性慢性粒细胞白血病细胞中均未显著降低伊马替尼的有机阳离子转运体1（OCT-1）活性。 - Suppr

Suppr

超能文献

Nilotinib does not significantly reduce imatinib OCT-1 activity in either cell lines or primary CML cells.

作者信息

Eadie L, Hughes T P, White D L

出版信息

Leukemia. 2010 Apr;24(4):855-7. doi: 10.1038/leu.2010.7. Epub 2010 Feb 11.

DOI:10.1038/leu.2010.7

PMID:20147980

Abstract

摘要

相似文献

Nilotinib does not significantly reduce imatinib OCT-1 activity in either cell lines or primary CML cells.

Leukemia. 2010 Apr;24(4):855-7. doi: 10.1038/leu.2010.7. Epub 2010 Feb 11.

Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity.

Leukemia. 2010 Apr;24(4):765-70. doi: 10.1038/leu.2010.16. Epub 2010 Feb 11.

Nilotinib and imatinib inhibit cytarabine cellular uptake: implications for combination therapy.

Leuk Res. 2012 Oct;36(10):1311-4. doi: 10.1016/j.leukres.2012.06.012. Epub 2012 Jul 12.

BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.

Blood. 2004 Apr 15;103(8):3167-74. doi: 10.1182/blood-2003-04-1271. Epub 2003 Dec 11.

OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib.

Blood. 2006 Jul 15;108(2):697-704. doi: 10.1182/blood-2005-11-4687. Epub 2006 Apr 4.

Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells.

J Clin Invest. 2009 May;119(5):1109-23. doi: 10.1172/JCI35660. Epub 2009 Apr 13.

Pml and TAp73 interacting at nuclear body mediate imatinib-induced p53-independent apoptosis of chronic myeloid leukemia cells.

Int J Cancer. 2009 Jul 1;125(1):71-7. doi: 10.1002/ijc.24329.

Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.

Clin Cancer Res. 2006 Oct 1;12(19):5869-78. doi: 10.1158/1078-0432.CCR-06-0980.

Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib.

Biomed Pharmacother. 2013 Mar;67(2):157-63. doi: 10.1016/j.biopha.2012.10.017. Epub 2012 Nov 19.

Overcoming CML acquired resistance by specific inhibition of Aurora A kinase in the KCL-22 cell model.

Carcinogenesis. 2012 Feb;33(2):285-93. doi: 10.1093/carcin/bgr278. Epub 2011 Nov 24.

引用本文的文献

Facilitated Transport of EGFR Inhibitors Plays an Important Role in Their Cellular Uptake.

Anal Chem. 2024 Jan 30;96(4):1547-1555. doi: 10.1021/acs.analchem.3c04242. Epub 2024 Jan 12.

Increased peroxisome proliferator-activated receptor γ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells.

Haematologica. 2017 May;102(5):843-853. doi: 10.3324/haematol.2016.153270. Epub 2017 Feb 2.

In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib.

J Hematol Oncol. 2015 Jul 7;8:81. doi: 10.1186/s13045-015-0179-4.

OCT1 and imatinib transport in CML: is it clinically relevant?

Leukemia. 2015 Oct;29(10):1960-9. doi: 10.1038/leu.2015.170. Epub 2015 Jul 9.

OCT-1, ABCB1, and ABCG2 Expression in Imatinib-Resistant Chronic Myeloid Leukemia Treated with Dasatinib or Nilotinib.

Chonnam Med J. 2014 Dec;50(3):102-11. doi: 10.4068/cmj.2014.50.3.102. Epub 2014 Dec 17.

Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy.

Leukemia. 2010 Jul;24(7):1299-301. doi: 10.1038/leu.2010.110. Epub 2010 Jun 3.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验